<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594684</url>
  </required_header>
  <id_info>
    <org_study_id>EK 11108</org_study_id>
    <nct_id>NCT01594684</nct_id>
  </id_info>
  <brief_title>Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries</brief_title>
  <official_title>Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Gunnar Tepe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zeller</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reimer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brechtel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diehm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strausinsky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jahnke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huppert</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amendt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Rosenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In stent restenosis in peripheral artery disease (superficial and popliteal artery) either
      treated with uncoated or paclitaxel coated balloons.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss (LLL)</measure>
    <time_frame>6 +/-2 months</time_frame>
    <description>• Late lumen loss (difference between the angiographic minimum lumen diameter (MLD) immediately and at 6 months post index procedure) evaluated by quantitative angiography. Analysis will be performed by an independent Angiographic Core Laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Procedural success</measure>
    <time_frame>after intervention</time_frame>
    <description>• Procedural success defined as ≤ 30% residual stenosis following the procedure at the target lesion (after prolonged dilation and stenting, if necessary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>• Clinically-driven target lesion revascularization (TLR) at 6, 12 and 24 months. Target lesion revascularization is defined as any reintervention or artery bypass graft surgery involving the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>• Target vessel revascularization (TVR) at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>• Binary restenosis rate at 6, 12 and 24 months.
o Binary restenosis defined as &gt; 50% diameter stenosis via angiography or PVR ≥ 2.4 via duplex ultrasound. In cases where results are available for both angiography and duplex ultrasound, angiographic results (if conducted within follow-up window) will be used to determine binary restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford category</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Change of Rutherford category post index procedure and at 6, 12, and 24 months as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancle Brachial index (ABI)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>• Change in ABI at 6, 12, and 24 months as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss (LLL)</measure>
    <time_frame>24 months</time_frame>
    <description>• LLL at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum lumen diameter (MLD)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>• MLD at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>• Hospitalization (extra days due to complications of the index procedure) and hospitalization between the follow-up visits due to the index lesion and index leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>30days</time_frame>
    <description>• Evaluation of 30 days freedom from procedure related death, unplanned amputation, and TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resteosis pattern</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>• Characterization of restenosis patterns between the two therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR), clinical success and angiographic outcome (restenosis rate, late lumen loss) after second therapy</measure>
    <time_frame>after intervention, 6, 12 and 24 months</time_frame>
    <description>clinical success, restensosis, TLR and LLL after second use of drug eluting balloons if initial therapy failed 30 days or later</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Catherization</condition>
  <arm_group>
    <arm_group_label>drug eluting balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with drug eltuing balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uncoated balloon</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment with uncoated balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double drug eluting balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>if treatment fails 30 days or later</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)</intervention_name>
    <description>balloon inflation</description>
    <arm_group_label>drug eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug coated balloon inflation (Cotavance, Medrad Inc.)</intervention_name>
    <description>Balloon inflation</description>
    <arm_group_label>drug eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated balloon (e.g. Admiral, Medtronic)</intervention_name>
    <description>balloon inflation</description>
    <arm_group_label>uncoated balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)</intervention_name>
    <description>ballon inflation</description>
    <arm_group_label>double drug eluting balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In-stent restenosis or re-occlusion at the target lesion due to an interventional
             treatment &gt; 3 months prior to enrollment.

          2. Has evidence of ≥ 70% stenosis or occlusion in the SFA and/or popliteal confirmed by
             angiography that is 3-27 cm long.

          3. Reference vessel diameter of 3 to 7 mm (reference vessel diameter = normal vessel
             diameter 1 cm proximal of the index lesion)

          4. Patients (men and women) with PAD disease category 2 to 5 according to Rutherford
             classification.

          5. Patient is eligible for an operative vascular intervention in case of complications
             during the procedure.

          6. Female patients of child bearing potential must have a negative pregnancy test 7 days
             at theprior to the time of intervention.

          7. Fully informed and signed consent must be obtained from each patient.

          8. Patients must be willing and able to continue study participation following study
             procedure in order to ensure completion of all procedures and observations required by
             protocol.

          9. Patient has evidence of at least one run off vessel that does not also require
             treatment for significant (≥ 50% stenosis or occlusion) stenosis during the index
             procedure to the ankle/foot of the limb to be treated. Treatment of infrapopliteal
             lesions must be staged at least 30 days before or after the index procedure.

         10. If restnosis occurs in both arms 30 days or later (re-re-sternosis)- treament with two
             drug eluting balloons at the same location (double dose)

        Exclusion Criteria:

          1. Patients with more than two lesions in the target vessel requiring treatment (if the
             distance between two lesions is less than 2 cm, the lesions should be counted as one
             lesion). The second lesion should also be treated with either coated or uncoated
             balloons (according to the randomization)

          2. Guidewire cannot cross lesion and/or an intentional subintimal approach in the stented
             lesion is required.

          3. Patients with stent fractures grade 2-4.

          4. Inflow lesion (proximal to the study lesion) with flow limitation not being
             successfully treated prior to treatment of the study lesion.

          5. Acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the
             treatment of the study lesion.

          6. Acutely occurring symptoms with a lyses or an operation as a therapeutic option within
             the last 6 weeks within the study limb.

          7. Potential loss of leg due to critical or acute ischemia.

          8. No patent distal run-off vessel.

          9. Aneurysm in the blood vessel intended for intervention in this study.

         10. Blood platelet count &lt; 100.000/mm3 or &gt;700.000/mm3, leukocyte count &lt; 3.000/mm3.

         11. Contra-indication to anticoagulation, or any anti-platelet agent (e.g. aspirin,
             heparin, clopidogrel, ticlopidine, abciximab), or paclitaxel.

         12. Known intolerance or contra-indication (e.g. severe hepatic (with ALAT and/or ASAT &gt; 3
             times the normal reference range) or renal (creatinine &gt; 1.1 mg/dl in women and &gt;1.5
             mg/dl in men) to contrast agents which cannot be adequately pre-treated, e.g. with
             adequate hydration.

         13. Severe illnesses such as cancer, liver or renal diseases, myocardial insufficiency
             leading to protocol deviations and/or a reduced life expectancy of less than 2 years.

         14. Manifest hyperthyreosis.

         15. Latent hyperthyreosis without adequate therapy, e.g., previous blocking with
             Natriumperchlorat (Irenat®).

         16. Significant gastrointestinal hemorrhage within the previous 6 months prior to study
             participation.

         17. History of hemorrhagic diathesis or coagulopathy or rejection of blood transfusions.

         18. Medical reason against double anti-platelet therapy in anti-coagulated patient, e.g.,
             receiving coumadine.

         19. Any severe medical condition that might interfere with the interpretation of the data
             or result in an unacceptable risk for the patient's participation in the study,
             according to the judgment of the clinical investigator.

         20. Female patient who is pregnant or lactating.

         21. Patient under 18 years of age.

         22. Participation in another clinical study up to 30 days prior to study entry.

         23. Previous participation in the same trialstudy (only one leg can be treated within the
             study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>BW</state>
        <zip>73000</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD</last_name>
      <phone>076334022431</phone>
      <email>thomas.zeller@herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tepe</name>
      <address>
        <city>Rosenheim</city>
        <state>BW</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Tepe, MD</last_name>
      <phone>80313653551</phone>
      <email>gunnar.tepe@ro-med.de</email>
    </contact>
    <investigator>
      <last_name>Gunnar Tepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <state>BW</state>
        <zip>73022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Brechtel, MD</last_name>
      <phone>070712983371</phone>
      <email>klaus.brechtel@uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jüdisches Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <zip>0001</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Duda, MD</last_name>
      <email>stefan.duda@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Duda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <state>DE</state>
        <zip>0001</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Albrecht, MD</last_name>
      <phone>030-2983366</phone>
      <email>thomas.albrecht@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Albrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Neumünster</name>
      <address>
        <city>Neumünster</city>
        <state>SH</state>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Jahnke, MD</last_name>
      <phone>04321 405-4910</phone>
      <email>thomas.jahnke@fek.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Jahnke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>June 16, 2012</last_update_submitted>
  <last_update_submitted_qc>June 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Rosenheim</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Gunnar Tepe</investigator_full_name>
    <investigator_title>Head of the Deparment of Diagnostic and Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>restenosis</keyword>
  <keyword>stent</keyword>
  <keyword>drug eltuing balloon</keyword>
  <keyword>peripheral arterial disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

